Ładuje się......
Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma
INTRODUCTION: Treatment of metastatic renal cell carcinoma (mRCC) has improved with the use of targeted therapies, but bone metastases continue to be negative prognostic factor. METHODS: Patients with mRCC treated with everolimus (EV) or sorafenib (SO) after two previous lines of targeted therapies...
Zapisane w:
| Wydane w: | Can Urol Assoc J |
|---|---|
| Główni autorzy: | , , , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Canadian Medical Association
2015
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4537338/ https://ncbi.nlm.nih.gov/pubmed/26316911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2377 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|